2. What is the Next-Generation Biomanufacturing Market size forecast for 2035?

The next-generation biomanufacturing market is forecast to reach USD 60.04 Billion by 2035.

4. Which equipment category dominates the Next-Generation Biomanufacturing Market?

Upstream systems dominates the next-generation biomanufacturing market, valued at USD 8.37 billion in 2025.

6. Which region leads the Next-Generation Biomanufacturing Market?

North America leads the next-generation biomanufacturing market, accounting for approximately 42% revenue share in 2025.

7. Which region is the fastest-growing in the Next-Generation Biomanufacturing Market?

Asia-Pacific is the fastest-growing region in the next-generation biomanufacturing market, expanding at a 12.6% CAGR from 2026 to 2035.

8. Which country holds the largest Next-Generation Biomanufacturing Market share?

The U.S. holds the largest country-level share, with a market size of approximately USD 8.07 billion in 2025.

10. What are the key growth drivers of the Next-Generation Biomanufacturing Market?

Expanding CDMO single-use capacity investment and rising cell and gene therapy manufacturing demand are key drivers, with the Upstream systems segment alone generating USD 8.37 billion in 2025.

11. What factors restrain Next-Generation Biomanufacturing Market growth?

The high capital cost of continuous and automated manufacturing conversion restrains adoption, affecting Biopharma Companies that account for approximately 54% of 2025 revenue.

12. What opportunities exist in the Next-Generation Biomanufacturing Market?

Integrated automation platforms and specialized cell and gene therapy media present strong opportunities, with the Cell therapy modality growing at a 14.4% CAGR from 2026 to 2035.

13. How is technology influencing the Next-Generation Biomanufacturing Market?

Real-time analytics and connected digital platforms are reshaping the market, with the Analytics and modelling software segment growing at a 13.3% CAGR.

14. What regulations shape the Next-Generation Biomanufacturing Market?

FDA guidance on advanced manufacturing technologies and process analytical technology shapes the roughly 34% share held by Upstream systems through validation-driven adoption timelines.

Next-Generation Biomanufacturing Market

Name: Next-Generation Biomanufacturing Market
Creator: Next Move Strategy Consulting
Published: 2026-10-03T00:00:00+00:00
License: https://www.nextmsc.com/privacy-policy

Research Methodology

At Next Move Strategy Consulting, we understand that insightful market research is the cornerstone of successful business decisions. That's why we employ a robust and multifaceted approach, combining various methodologies to deliver the most accurate and actionable data for our clients.

Research Methodology Nmsc Updated

Research Landscape

We navigate the world of research with two primary approaches:

Qualitative Approach

Our qualitative research methodologies involve immersive techniques such as in-depth interviews, focus groups, and observational studies. By engaging directly with individuals and stakeholders, we uncover valuable insights that quantitative data alone may overlook.

Quantitative Research

In tandem with qualitative methodologies, NMSC leverages the power of Quantitative Research to provide a robust foundation of numerical insights. Through systematic data collection and analysis, we quantify patterns, preferences, and market trends, offering a comprehensive view of the business landscape.

Our quantitative research approach employs diverse tools, including surveys, experiments, and statistical modelling. These methodologies enable us to gather data from a large and representative sample, ensuring the statistical significance of our findings. By employing structured questionnaires and standardized data collection methods, we guarantee the reliability and validity of the information we present to our clients.

Quantitative research is particularly effective in measuring the prevalence of trends, assessing market size, and gauging the impact of various factors on consumer behavior. The numerical precision attained through this approach equips our clients with actionable insights, facilitating data-driven decision-making and strategy formulation.

Our Specialized Toolbox for Industry-Specific Market Research

We deploy a specialized arsenal of techniques tailored to meet your unique requirements. Here's a glimpse into our comprehensive toolbox:

Information Procurement

The stage entails acquiring market data or relevant information through various sources and methodologies.

Market Research Approach

We utilize both top-down and bottom-up approaches in market research analysis to achieve a comprehensive understanding of the market dynamics, leveraging the broad perspective of industry trends and macroeconomic factors alongside detailed insights from specific segments and individual companies.

Porters Five Forces Analysis

We conduct Porter's Five Forces analysis to evaluate the competitive landscape of an industry, providing us with insights into factors that affect profitability and strategic positioning.

Porters 5 Updated 2

SWOT Analysis

Forecasting

We utilize a forecasting model to predict future consumption by considering parameters like population, economics, regulations, market competition, drivers, constraints, technology, and pricing. We also employ statistical techniques such as multilinear regression, exponential smoothing, moving average, ARIMA, and Monte Carlo simulations for accurate predictions. In econometric forecasting, we analyzed short-term and long-term event impacts, attributing values based on regulatory frameworks, economic factors, and market events.

What Is the Next-Generation Biomanufacturing Market Size?

The global next-generation biomanufacturing market size was valued at USD 24.63 Billion in 2025 and is estimated at USD 26.93 Billion in 2026, forecast to reach USD 60.04 Billion by 2035, expanding at a 9.32% CAGR between 2026 and 2035. North America leads with approximately a 42% share, while Upstream systems dominate all other equipment categories with approximately a 34% share.

We observed that growth is broadest in automation, cell and gene therapy, and CDMO-oriented categories, with continuous bioprocessing architectures and Asia-Pacific capacity expansion recording the strongest structural gains through 2035.

Next-Generation Biomanufacturing Market Revenue Forecast

Values in USD Billion

2025 $24.63 Billion

2025

2026 $26.93 Billion

2026

2027 $29.43 Billion

2027

2028 $32.18 Billion

2028

2029 $35.18 Billion

2029

2030 $38.46 Billion

2030

2031 $42.04 Billion

2031

2032 $45.96 Billion

2032

2033 $50.24 Billion

2033

2034 $54.92 Billion

2034

2035 $60.04 Billion

2035

Key Takeaways

By Equipment: Upstream systems held the largest share of approximately 34% (USD 8.37 billion) in 2025; Automation and robotics is the fastest-growing sub-segment at 12.7% CAGR from 2026-2035.

By Consumables and raw materials: Single-use assemblies held the largest share of approximately 32% (USD 7.88 billion) in 2025; Sensors and probes is the fastest-growing sub-segment at 13.1% CAGR from 2026-2035.

By Software and Digital Platforms: Automation software held the largest share of approximately 38% (USD 9.36 billion) in 2025; Analytics and modelling is the fastest-growing sub-segment at 13.3% CAGR from 2026-2035.

By Technical services: CDMO and contract manufacturing held the largest share of approximately 30% (USD 7.39 billion) in 2025; Engineering and integration is the fastest-growing sub-segment at 12.4% CAGR from 2026-2035.

By Workflow step: Upstream held the largest share of approximately 34% (USD 8.37 billion) in 2025; Analytics and control is the fastest-growing sub-segment at 13.0% CAGR from 2026 to 2035.

By Technology architecture: Single-use held the largest share of approximately 42% (USD 10.35 billion) in 2025; Continuous is the fastest-growing sub-segment at 14.4% CAGR from 2026-2035.

By Modality: Monoclonal antibodies held the largest share of approximately 32% (USD 7.88 billion) in 2025; Cell therapy is the fastest-growing sub-segment at 14.4% CAGR from 2026-2035.

By End Users: Biopharma Companies held the largest share of approximately 54% (USD 13.30 billion) in 2025; CDMOs and CMOs is the fastest-growing sub-segment at 12.0% CAGR from 2026-2035.

By Sales channel: Direct key accounts held the largest share of approximately 48% (USD 11.82 billion) in 2025; Contract service is the fastest-growing sub-segment at 12.5% CAGR from 2026-2035.

Dominant Region: North America dominated with approximately 42% revenue share (USD 10.35 billion) in 2025.

Fastest-Growing Region: Asia-Pacific is expected to register the highest CAGR of 12.6% during 2026-2035.

Dominant Country: The U.S. led with approximately USD 8.07 billion in 2025.

Fastest-Growing Country: India is the fastest-growing country at approximately 14.8% CAGR from 2026-2035.

Market Opportunity: The next-generation biomanufacturing market is expected to create an absolute dollar opportunity of USD 33.11 billion between 2026 and 2035, presenting significant investment potential across automation, continuous bioprocessing, and cell and gene therapy manufacturing platforms.

According to NMSC analysis, equipment vendors are increasingly bundling hardware with digital analytics and automation software into unified platforms, a shift that favors suppliers capable of delivering integrated upstream-to-downstream solutions over component-only vendors as biopharma and CDMO customers consolidate procurement relationships through 2035.

Ecosystem Analysis of the Next-Generation Biomanufacturing Industry

The above infographic presents an ecosystem analysis of the next-generation biomanufacturing market, covering bioprocess platforms, single-use technologies, therapy applications, automation systems, research networks, digital controls, and quality oversight. Cell-free systems and continuous platforms are accelerating protein production, while single-use bioreactors reduce cleaning requirements and enhance operational flexibility. AI and digital twins are optimizing bioprocess settings and design accuracy, while robotic automation minimizes manual intervention. Cell and gene therapies are driving demand for flexible manufacturing platforms, supported by regulatory guidance and quality standards. Looking ahead, we observed that integration of advanced automation and digital tools will remain central to improving efficiency and scalability across the biopharmaceutical sector.

What Does the Next-Generation Biomanufacturing Market Encompass?

The next-generation biomanufacturing market encompasses the equipment, consumables, software, and technical services used to produce biologics through single-use, continuous, and digitally enabled manufacturing architectures. Our assessment indicates that the scope spans upstream and downstream processing systems, fill-finish equipment, automation and robotics, single-use consumables, and analytics platforms, supplied to biopharma companies, CDMOs, and research institutions across monoclonal antibody, cell therapy, gene therapy, and mRNA production workflows.
Regulatory frameworks, including the U.S. FDA's guidance on advanced manufacturing technologies and process analytical technology, continue to shape adoption timelines for continuous and digitally monitored production systems. We observed that technology adoption is shifting toward integrated automation and analytics platforms, as CDMOs pursuing single-use bioprocessing capacity expansion increasingly specify digitally connected equipment across the next-generation biomanufacturing market.

Key Emerging Trends

Based on research conducted by NMSC, we found that four structural trends are reshaping technology adoption, sourcing strategy, and stakeholder engagement across the industry.

How Is Intensified Downstream Processing Reshaping Purification Workflows?

Equipment vendors are increasingly combining multicolumn chromatography with integrated ultrafiltration and diafiltration into single, connected downstream modules. We observed that Sartorius AG's July 2026 launch of Pionic Quad and Pionic Cross for intensified downstream processing illustrates how manufacturers are consolidating previously separate purification unit operations into unified, continuous platforms that reduce footprint and improve traceability across regulated production campaigns.

Why Is Large-Scale Single-Use Capacity Expansion Accelerating Among CDMOs?

CDMOs are commissioning increasingly large single-use manufacturing facilities to meet growing biologics demand without the multi-year lead times associated with stainless-steel construction. Our findings suggest that this trend is accelerating fastest across biopharmaceutical CDMO capacity expansion, as Samsung Biologics Co., Ltd.'s April 2025 operationalization of Plant 5, adding approximately 180,000 liters of capacity, demonstrates how CDMOs are scaling single-use infrastructure to secure long-term biologics manufacturing contracts.

How Is At-Line Analytics Technology Compressing Bioprocess Decision Cycles?

Analytics vendors are increasingly developing at-line measurement systems that return results in seconds rather than requiring samples to be sent to separate laboratory instruments. We found that Repligen Corporation's January 2025 launch of the CTech SoloVPE PLUS system, which returns protein concentration results within thirty seconds, illustrates how real-time analytics are compressing bioprocess decision cycles and supporting standardized data communication across connected manufacturing workflows.

What Role Does Specialized Cell and Gene Therapy Media Play in Manufacturing Scale-Up?

Media and reagent suppliers are increasingly developing specialized, GMP-compliant formulations tailored to specific cell and gene therapy modalities rather than general-purpose cell culture media. We observed that Lonza Group AG's October 2025 launch of TheraPEAK AmpliCell Cytokines and TheraPEAK 293-GT Medium illustrates how suppliers are extending dedicated product lines to support immune cell expansion and AAV production, addressing the specialized input requirements of advanced therapy manufacturing at scale.

Market Drivers & Dynamics

Interactive Dataset


Expanding CDMO single-use capacity investment	driver	+2.4%	North America, Asia-Pacific	2026-2035
Rising cell and gene therapy manufacturing demand	driver	+2.1%	Global	2026-2035
Growing adoption of automation and robotics in bioprocessing	driver	+1.7%	North America, Europe	2026-2035
Increasing integration of at-line and real-time analytics	driver	+1.3%	Global	2026-2035
Expanding biomanufacturing capacity investment in Asia-Pacific	driver	+1.1%	Asia-Pacific	2026-2035
Growing outsourcing of biologics manufacturing to CDMOs	driver	+0.9%	Global	2026-2032
High capital cost of continuous and automated manufacturing conversion	restraint	-1.2%	Global	2026-2035
Regulatory validation burden for novel manufacturing technologies	restraint	-0.8%	North America, Europe	2026-2035
Shortage of skilled bioprocess engineering talent	restraint	-0.6%	Global	2026-2032

Source: Next Move Strategy Consulting

Growth Drivers

What Is the Primary Growth Driver of the Next-Generation Biomanufacturing Market?

Expanding CDMO single-use capacity investment is the primary driver of the market. The National Institute for Innovation in Manufacturing Biopharmaceuticals continues to fund technology and workforce development projects supporting advanced biomanufacturing capacity. We observed that this capacity investment, reinforced by Samsung Biologics' 2025 facility expansion, sustains baseline demand for upstream and downstream single-use systems across CDMO and biopharma company end users.

How Is Cell and Gene Therapy Demand Driving Market Growth?

Rising cell and gene therapy manufacturing demand is accelerating market growth as these modalities require specialized, smaller-batch production equipment distinct from traditional monoclonal antibody manufacturing. The National Institute of Standards and Technology continues to document growing federal investment in biomanufacturing process control data infrastructure. Our assessment indicates that this demand growth is accelerating adoption timelines for specialized cell and gene therapy manufacturing equipment and media across North American and European advanced therapy production facilities.

Growth Inhibitors

What Is Restraining Next-Generation Biomanufacturing Market Expansion?

The high capital cost of continuous and automated manufacturing conversion restrains adoption among smaller biopharma companies with constrained capital budgets. The U.S. Securities and Exchange Commission's public filings from major equipment suppliers continue to document the capital-intensive nature of advanced bioprocessing technology investment. We found that smaller biopharma companies face particular exposure, as limited capital availability constrains their ability to adopt continuous and automated manufacturing platforms relative to larger, well-capitalized CDMOs and biopharma companies.

Segmentation Analysis

2025 (USD Billion)

2035 (USD Billion)

Upstream systems 2025: $8.37 Billion | 2035: $19.76 Billion

Upstream sys

Downstream systems 2025: $6.40 Billion | 2035: $15.62 Billion

Downstream s

Fill finish systems 2025: $3.94 Billion | 2035: $9.07 Billion

Fill finish

Automation and robotics 2025: $3.45 Billion | 2035: $10.15 Billion

Automation a

Other equipment 2025: $2.46 Billion | 2035: $5.44 Billion

Other equipm


Upstream systems	$8.37 Billion	$19.76 Billion	10.0%
Downstream systems	$6.40 Billion	$15.62 Billion	10.4%
Fill finish systems	$3.94 Billion	$9.07 Billion	9.7%
Automation and robotics	$3.45 Billion	$10.15 Billion	12.7%
Other equipment	$2.46 Billion	$5.44 Billion	9.2%

Which Equipment Segment Dominates the Next-Generation Biomanufacturing Market?

Upstream systems led the market with USD 8.37 billion in 2025, supported by sustained demand for bioreactor and fermenter capacity across biologics production. We observed that Automation and robotics is the fastest-growing equipment category, expanding at a 12.7% CAGR from 2026 to 2035, as manufacturers increasingly specify liquid handling robots and process control hardware to reduce manual intervention and improve production consistency.

2025 (USD Billion)

2035 (USD Billion)

Single-use a

Bags and con

Tubing and m

Connectors a

Other single

Segment Item	2025 (USD Billion)	2035 (USD Billion)	CAGR
Single-use assemblies	$10.0 USD Billion	$40.0 USD Billion	25.0%
Bags and containers	$17.1 USD Billion	$51.1 USD Billion	11.0%
Tubing and manifolds	$24.2 USD Billion	$62.2 USD Billion	25.0%
Connectors and disconnectors	$31.3 USD Billion	$73.3 USD Billion	11.0%
Other single-use assemblies	$38.4 USD Billion	$84.4 USD Billion	16.0%

Segment-wise data is locked

Unlock complete segment-wise numbers for By Consumables and raw materials.

Unlock Full Data

2025 (USD Billion)

2035 (USD Billion)

Data managem

Historian

Batch record

LIMS

Analytics an

Segment Item	2025 (USD Billion)	2035 (USD Billion)	CAGR
Data management	$10.0 USD Billion	$40.0 USD Billion	27.0%
Historian	$17.1 USD Billion	$51.1 USD Billion	9.0%
Batch records	$24.2 USD Billion	$62.2 USD Billion	19.0%
LIMS	$31.3 USD Billion	$73.3 USD Billion	17.0%
Analytics and modelling	$38.4 USD Billion	$84.4 USD Billion	18.0%

Segment-wise data is locked

Unlock complete segment-wise numbers for By Software and Digital Platforms.

Unlock Full Data

2025 (USD Billion)

2035 (USD Billion)

Process deve

Tech transfe

CDMO and con

Engineering

Quality cont

Segment Item	2025 (USD Billion)	2035 (USD Billion)	CAGR
Process development	$10.0 USD Billion	$40.0 USD Billion	14.0%
Tech transfer and validation	$17.1 USD Billion	$51.1 USD Billion	24.0%
CDMO and contract manufacturing	$24.2 USD Billion	$62.2 USD Billion	22.0%
Engineering and integration	$31.3 USD Billion	$73.3 USD Billion	12.0%
Quality control and testing	$38.4 USD Billion	$84.4 USD Billion	27.0%

Segment-wise data is locked

Unlock complete segment-wise numbers for By Technical services.

Unlock Full Data

2025 (USD Billion)

2035 (USD Billion)

Upstream

Downstream

Fill-finish

Analytics an

Cross-functi

Segment Item	2025 (USD Billion)	2035 (USD Billion)	CAGR
Upstream	$10.0 USD Billion	$40.0 USD Billion	24.0%
Downstream	$17.1 USD Billion	$51.1 USD Billion	22.0%
Fill-finish	$24.2 USD Billion	$62.2 USD Billion	20.0%
Analytics and control	$31.3 USD Billion	$73.3 USD Billion	22.0%
Cross-functional	$38.4 USD Billion	$84.4 USD Billion	13.0%

Segment-wise data is locked

Unlock complete segment-wise numbers for By Workflow step.

Unlock Full Data

2025 (USD Billion)

2035 (USD Billion)

Single-use

Stainless st

Continuous

Modular

Hybrid

Segment Item	2025 (USD Billion)	2035 (USD Billion)	CAGR
Single-use	$10.0 USD Billion	$40.0 USD Billion	23.0%
Stainless steel	$17.1 USD Billion	$51.1 USD Billion	9.0%
Continuous	$24.2 USD Billion	$62.2 USD Billion	19.0%
Modular	$31.3 USD Billion	$73.3 USD Billion	13.0%
Hybrid	$38.4 USD Billion	$84.4 USD Billion	10.0%

Segment-wise data is locked

Unlock complete segment-wise numbers for By Technology architecture.

Unlock Full Data

2025 (USD Billion)

2035 (USD Billion)

Monoclonal a

Vaccines

Cell therapy

Gene therapy

Recombinant

Segment Item	2025 (USD Billion)	2035 (USD Billion)	CAGR
Monoclonal antibodies	$10.0 USD Billion	$40.0 USD Billion	21.0%
Vaccines	$17.1 USD Billion	$51.1 USD Billion	23.0%
Cell therapy	$24.2 USD Billion	$62.2 USD Billion	25.0%
Gene therapy	$31.3 USD Billion	$73.3 USD Billion	15.0%
Recombinant proteins	$38.4 USD Billion	$84.4 USD Billion	16.0%

Segment-wise data is locked

Unlock complete segment-wise numbers for By Modality.

Unlock Full Data

Which Modality Segment Leads Next-Generation Biomanufacturing Market Demand?

Monoclonal antibodies remained the dominant modality, valued at USD 7.88 billion in 2025, due to their established role as the largest and most mature category of manufactured biologics. Our findings suggest that Cell therapy is the fastest-growing modality, registering a 14.4% CAGR from 2026 to 2035, as expanding clinical approvals and manufacturing scale-up drive demand for specialized, smaller-batch production equipment and consumables.

2025 (USD Billion)

2035 (USD Billion)

Biopharma Co

CDMOs and CM

Academic and

Government a

Segment Item	2025 (USD Billion)	2035 (USD Billion)	CAGR
Biopharma Companies	$10.0 USD Billion	$40.0 USD Billion	9.0%
CDMOs and CMOs	$17.1 USD Billion	$51.1 USD Billion	23.0%
Academic and Research Institutions	$24.2 USD Billion	$62.2 USD Billion	9.0%
Government and Public labs	$31.3 USD Billion	$73.3 USD Billion	23.0%

Segment-wise data is locked

Unlock complete segment-wise numbers for By End Users.

Unlock Full Data

Which End User Segment Is Most Widely Served in the Market?

Biopharma Companies remained the dominant end user, reaching USD 13.30 billion in 2025 due to concentrated in-house manufacturing investment across large pharmaceutical and biotechnology organizations. Based on research conducted by NMSC, we found that CDMOs and CMOs is the fastest-growing end user at a 12.0% CAGR from 2026 to 2035, reflecting rising outsourcing of biologics manufacturing to contract organizations with specialized advanced therapy production capacity.

2025 (USD Billion)

2035 (USD Billion)

Direct key a

Distributor

System integ

E-commerce a

Contract ser

Segment Item	2025 (USD Billion)	2035 (USD Billion)	CAGR
Direct key accounts	$10.0 USD Billion	$40.0 USD Billion	23.0%
Distributor	$17.1 USD Billion	$51.1 USD Billion	21.0%
System integrator	$24.2 USD Billion	$62.2 USD Billion	15.0%
E-commerce and catalogue	$31.3 USD Billion	$73.3 USD Billion	9.0%
Contract service	$38.4 USD Billion	$84.4 USD Billion	10.0%

Segment-wise data is locked

Unlock complete segment-wise numbers for By Sales channel.

Unlock Full Data

Growth Opportunities

Our analysis shows that three forward-looking opportunities stand out for stakeholders positioning within the next-generation biomanufacturing market over the 2026-2035 forecast period.

How Can Integrated Automation Platforms Unlock Value for CDMOs?

Integrated automation and analytics platforms present a whitespace opportunity for vendors serving CDMOs pursuing simplified, digitally connected manufacturing operations. Suppliers that commercialize bundled hardware-software offerings stand to capture recurring software and service revenue as CDMOs standardize digital infrastructure across expanding single-use production capacity.

Where Does Specialized Cell and Gene Therapy Media Create New Demand?

Advanced therapy manufacturers represent an underpenetrated opportunity for specialized, GMP-compliant media and reagents tailored to specific cell and gene therapy modalities. Providers that develop application-specific inputs supporting cell and gene therapy manufacturing can secure long-term supply contracts with biopharma companies and CDMOs scaling advanced therapy production.

How Can Real-Time Analytics Benefit Continuous Manufacturing Adopters?

Manufacturers transitioning toward continuous bioprocessing create an opportunity for vendors offering real-time, at-line analytics that support connected, regulated production campaigns. Early movers that streamline rapid measurement technology integration can differentiate with biopharma companies and CDMOs pursuing standardized, data-driven continuous manufacturing infrastructure.

Regional Outlook

2025 (USD Billion)

2035 (USD Billion)

North Americ

Europe

Asia-Pacific

Middle East

Latin Americ

Region	2025 (USD Billion)	2035 (USD Billion)	CAGR (%)
North America	$10.0 USD Billion	$40.0 USD Billion	9.0%
Europe	$17.1 USD Billion	$51.1 USD Billion	27.0%
Asia-Pacific	$24.2 USD Billion	$62.2 USD Billion	25.0%
Middle East & Africa	$31.3 USD Billion	$73.3 USD Billion	23.0%
Latin America	$38.4 USD Billion	$84.4 USD Billion	12.0%

Regional data is locked

Unlock complete regional numbers for this market.

Unlock Full Data

North America

2025 Size

$10.35 Billion

CAGR

9.7%

North America leads the next-generation biomanufacturing market with an established base of biopharma R&D investment and expanding CDMO manufacturing capacity. We observed that continued single-use bioreactor scale-up and growing cell and gene therapy production sustain demand for both equipment and specialized consumables. Technology adoption remains advanced, with integrated automation and analytics platforms driving demand across the region's largest biopharma and CDMO accounts.

Primary Driver: Concentrated biopharma R&D investment and expanding CDMO capacity

Key National Markets

U.S.

Based on our estimates, the U.S. market was valued at approximately USD 8.07 billion in 2025 and is projected to reach USD 16.54 billion by 2035, growing at an 8.3% CAGR. Demand is anchored by extensive biopharma R&D investment and expanding CDMO single-use manufacturing capacity. Technology penetration favors integrated automation and analytics platforms, and competitive intensity remains high among established equipment and consumables vendors serving national biopharma and CDMO accounts.

Canada

The market in Canada reached roughly USD 1.35 billion in 2025 and is forecast to hit USD 2.69 billion by 2035 at an 8.0% CAGR. Demand structure mirrors U.S. biopharma and CDMO adoption patterns, with growing federal investment in domestic biomanufacturing capacity. Technology penetration is rising as manufacturers request single-use and continuous processing systems, with competitive intensity moderate given reliance on cross-border equipment supply from U.S.-based vendors.

Europe

2025 Size

$6.40 Billion

CAGR

9.3%

Europe's next-generation biomanufacturing market reflects a mature, technology-intensive landscape shaped by a strong domestic upstream and downstream equipment manufacturing base. Our findings suggest that manufacturers across Germany, France, and the UK are accelerating adoption of intensified downstream processing modules. Technology adoption favors connected, continuous manufacturing platforms, supported by regional equipment suppliers including Sartorius AG and Eppendorf SE investing in digital bioprocessing innovation.

Primary Driver: Strong upstream and downstream equipment manufacturing base

Key National Markets

As per our estimate, the UK market stood at about USD 1.15 billion in 2025, advancing toward USD 2.27 billion by 2035 at a 7.8% CAGR. Demand is driven by established biopharma manufacturing and growing cell and gene therapy production investment. Regulatory influence from UK medicines and healthcare products regulatory requirements is notable, technology penetration favors continuous manufacturing adoption, and competitive intensity remains steady among domestic and European suppliers.

Germany

According to our analysis, Germany's market was valued near USD 1.67 billion in 2025 and is set to reach USD 3.44 billion by 2035, expanding at an 8.4% CAGR. Demand structure benefits from Germany's strong domestic bioprocessing equipment manufacturing base led by Sartorius AG and Eppendorf SE. Regulatory influence from European Medicines Agency requirements shapes procurement specifications, while technology penetration favors intensified downstream processing among leading manufacturers.

France

Based on our estimates, France's market reached approximately USD 0.83 billion in 2025, projected to climb to USD 1.61 billion by 2035 at a 7.6% CAGR. Demand is supported by France's expanding vaccine manufacturing base and national biomanufacturing investment initiatives. Regulatory influence from national health authority requirements is notable, and competitive intensity remains moderate given the concentration of regional integrators serving domestic biopharma accounts.

Asia-Pacific

2025 Size

$5.91 Billion

CAGR

12.6%

Asia-Pacific is the fastest-growing region, propelled by rapid CDMO capacity expansion across China and South Korea. We found that regulatory frameworks remain less harmonized than in Europe, giving equipment suppliers flexibility to scale distribution rapidly. Technology adoption is accelerating as regional CDMOs including Samsung Biologics Co., Ltd. and WuXi Biologics (Cayman) Inc. expand single-use and continuous manufacturing capacity to serve growing global biologics demand.

Primary Driver: Rapid CDMO capacity expansion in China and South Korea

Key National Markets

China

The market in China stood at roughly USD 1.77 billion in 2025 and is forecast to reach USD 5.12 billion by 2035, registering a 12.5% CAGR. Demand is fueled by rapid domestic CDMO capacity expansion and a dense base of regional biologics manufacturers, including WuXi Biologics (Cayman) Inc. Regulatory influence is increasing gradually, technology penetration is accelerating through domestic manufacturing capacity investment, and competitive intensity remains elevated among numerous China-based CDMOs.

India

As per our estimate, India's market was valued at about USD 0.89 billion in 2025, projected to reach USD 3.07 billion by 2035 at a 14.8% CAGR, the fastest among covered countries. Demand structure reflects rising vaccine manufacturing capacity and expanding domestic biopharma investment. Regulatory influence remains developing, while technology penetration is rising quickly as global equipment suppliers localize distribution to serve India's growing biomanufacturing base.

Japan

According to our analysis, Japan's market reached close to USD 0.95 billion in 2025 and is expected to hit USD 2.14 billion by 2035, growing at a 9.5% CAGR. Demand is supported by Japan's established biopharma manufacturing base led by domestic suppliers including Shimadzu Corporation. Regulatory influence is well established, technology penetration is advanced, and competitive intensity remains high among long-standing domestic and multinational vendors.

South Korea

Based on our estimates, South Korea's market stood at approximately USD 0.65 billion in 2025, forecast to reach USD 1.77 billion by 2035 at an 11.8% CAGR. Demand structure benefits from the country's rapidly expanding CDMO capacity, led by Samsung Biologics Co., Ltd.'s continued facility investment. Technology penetration is high, with domestic CDMOs supplying single-use manufacturing capacity, and competitive intensity remains pronounced amid rapid capacity expansion cycles.

Australia

The next-generation biomanufacturing market in Australia reached about USD 0.30 billion in 2025 and is projected to reach USD 0.70 billion by 2035, expanding at a 10.0% CAGR. Demand is supported by growing vaccine manufacturing investment and expanding domestic biopharma production capacity. Regulatory influence stems from national therapeutic goods guidance, while technology penetration favors single-use systems amid moderate competitive intensity.

Middle East & Africa

2025 Size

$1.23 Billion

CAGR

10.9%

The next-generation biomanufacturing market in the Middle East & Africa is expanding as Gulf Cooperation Council economies invest in emerging biomanufacturing infrastructure and localization initiatives. Our analysis shows that Saudi Arabia and the UAE are attracting biomanufacturing investment tied to national healthcare self-sufficiency programs. Regulatory influence remains developing, while technology adoption is gradually shifting toward single-use manufacturing platforms as regional facilities scale initial production capacity.

Primary Driver: Emerging biomanufacturing infrastructure investment and localization initiatives

Key National Markets

Saudi Arabia

According to our analysis, Saudi Arabia's market reached roughly USD 0.32 billion in 2025 and is expected to hit USD 0.77 billion by 2035, growing at a 10.3% CAGR. Demand is driven by Vision 2030-linked healthcare self-sufficiency investment and expanding domestic biomanufacturing infrastructure. Regulatory influence is developing under national health guidelines, and technology penetration is advancing as domestic and multinational vendors scale supply.

UAE

As per our estimate, the UAE market was valued near USD 0.35 billion in 2025, projected to reach USD 0.81 billion by 2035 at a 10.0% CAGR. Demand structure is shaped by the UAE's role as a regional healthcare self-sufficiency and biomanufacturing investment hub. Regulatory influence remains moderate, technology penetration is improving through single-use manufacturing adoption, and competitive intensity is rising as vendors expand regional service portfolios.

South Africa

Based on our estimates, South Africa's market stood at about USD 0.12 billion in 2025, forecast to reach USD 0.26 billion by 2035 at an 8.6% CAGR. Demand structure reflects a developing biomanufacturing infrastructure serving regional Southern African markets. Regulatory influence remains moderate, technology penetration is gradually improving, and competitive intensity is limited given reliance on equipment supply from international vendors.

Latin America

2025 Size

$0.74 Billion

CAGR

10.1%

Latin America's market is supported by growing vaccine and biologics production capacity investment across Brazil and Argentina. We observed that regulatory frameworks are less stringent than in North America or Europe, though multinational manufacturers operating locally are introducing standardized equipment specifications. Technology adoption remains centered on established upstream systems, with competitive intensity increasing as regional integrators partner with global equipment suppliers.

Primary Driver: Growing vaccine and biologics production capacity investment

Key National Markets

Brazil

The market in Brazil reached approximately USD 0.33 billion in 2025 and is projected to reach USD 0.73 billion by 2035, registering a 9.4% CAGR. Demand is underpinned by Brazil's large domestic vaccine manufacturing base and expanding biologics production investment. Regulatory influence stems from national health regulatory requirements, technology penetration favors upstream systems, and competitive intensity remains moderate among regional integrators.

Argentina

As per our estimate, Argentina's market was valued near USD 0.11 billion in 2025, projected to reach USD 0.23 billion by 2035 at an 8.4% CAGR. Demand structure is supported by steady vaccine and biologics manufacturing investment despite macroeconomic volatility. Regulatory influence remains limited, technology penetration is modest, and competitive intensity is centered on a small number of regional integrators serving domestic biopharma accounts.

Supply Chain Analysis of the Next-Generation Biomanufacturing Industry

The above infographic presents the supply chain structure of the next-generation biomanufacturing market, segmented into upstream and downstream activities. Engineered cells and growth media support bioprocess development, with advanced bioreactors and continuous systems improving control and efficiency. Single-use platforms and sensors enable clean processing, while GMP compliance and batch testing ensure quality. Downstream, cold chain logistics protect biological materials for delivery to biopharma firms and CDMOs. End-use applications include biologics and cell therapies. Looking ahead, we observed that process support and maintenance services remain essential for optimizing performance and reducing downtime across the biomanufacturing industry.

Competitive Landscape

We observed that the next-generation biomanufacturing market features a moderately consolidated competitive landscape, with diversified life sciences majors competing alongside specialized bioprocessing vendors on equipment breadth, digital integration depth, and global manufacturing footprint. Key Takeaways

Dimension	Description
Market Structure	Moderately consolidated; the top companies profiled in this report collectively account for a majority of global next-generation biomanufacturing revenue, while numerous specialized analytics and consumables vendors serve niche process categories.
Innovation Focus	Intensified downstream processing, at-line real-time analytics, and specialized cell and gene therapy media dominate current innovation pipelines across leading vendors.
M&A Activity	Selective capacity and capability expansion, exemplified by Samsung Biologics' Plant 5 commissioning and continued single-use bioreactor platform scale-up across major equipment suppliers.

How Do Companies Compete in the Next-Generation Biomanufacturing Market?

Companies compete primarily on equipment breadth, digital integration depth, and global manufacturing footprint across the industry. Diversified life sciences majors such as Thermo Fisher Scientific Inc. and Danaher Corporation leverage broad upstream-to-downstream portfolios to serve multinational biopharma customers, while specialized vendors such as Repligen Corporation and Sartorius AG compete on process-specific analytics and purification innovation for demanding continuous manufacturing applications.

Which Competitive Archetypes Dominate the Next-Generation Biomanufacturing Market?

Two archetypes dominate the market: diversified life sciences equipment majors offering integrated upstream, downstream, and digital platform portfolios, and specialized process technology vendors focused on analytics, purification, or media innovation. Thermo Fisher Scientific Inc. and Sartorius AG exemplify the diversified archetype through combined hardware and software offerings, while Repligen Corporation and Eppendorf SE exemplify the specialist archetype serving analytics and laboratory-adjacent bioprocessing niches.

How Are Companies Differentiating Through Innovation in the Market?

Innovation and differentiation strategy increasingly center on intensified, connected processing modules and real-time analytics integration. Sartorius's Pionic Quad and Cross downstream modules and Repligen's CTech SoloVPE PLUS at-line analytics both illustrate how vendors are compressing manufacturing footprint and decision cycles simultaneously. Our analysis shows that vendors unable to demonstrate connected, data-driven platform capabilities risk exclusion from CDMO and biopharma procurement, where digital integration increasingly shapes vendor selection.

What M&A and Expansion Activity Is Shaping the Next-Generation Biomanufacturing Market?

Capacity expansion and product line extension continue to shape competitive positioning within the industry more than large-scale acquisitions at this stage of market maturity. Samsung Biologics' Plant 5 commissioning and Lonza's TheraPEAK portfolio expansion illustrate how both CDMOs and equipment suppliers pursue capability growth through organic investment. These moves illustrate how diversified groups pursue geographic expansion and manufacturing scale across biopharma, CDMO, and research institution customer segments.

Key Market Players

Our assessment indicates that the following companies are actively shaping equipment innovation, digital platform integration, and go-to-market strategy within the global next-generation biomanufacturing market.

Thermo Fisher Scientific Inc. Danaher Corporation Merck KGaA, Darmstadt, Germany Sartorius AG Lonza Group AG Samsung Biologics Co., Ltd. WuXi Biologics (Cayman) Inc. FUJIFILM Biotechnologies Avantor, Inc. Corning Incorporated Solventum Corporation Repligen Corporation Bio-Rad Laboratories, Inc. Waters Corporation Agilent Technologies, Inc. Eppendorf SE Emerson Electric Co. Bruker Corporation Shimadzu Corporation Asahi Kasei Life Science Corp

Latest Developments

We found that recent product and capacity announcements within the next-generation biomanufacturing market are concentrated on intensified downstream processing and single-use capacity expansion, reflecting the industry's broader shift toward connected, scalable production architectures.

Date	Event
July 2026	Sartorius reported that multiple Pionic modules operated together as one coordinated downstream process for 72 hours in May 2026.
February 2026	FUJIFILM Biotechnologies opened its expanded Teesside, UK site following approximately USD 540 million of investment. The facility adds 2,000-L and 5,000-L single-use bioreactors, with a total capacity of up to 19,000 liters, for small- and mid-scale antibody manufacturing.
August 2025	WuXi Biologics announced that its WuXiU intensified perfusion platform achieved fully automated continuous drug-substance production at pilot scale.

Expert Insights

Justin Byers

Founder and CEO | Axio BioPharma

"“AI in biomanufacturing has to be grounded in the realities of how biologics are actually developed, transferred, manufactured, and regulated.”"

Analyst Interpretation

The statement highlights the growing shift toward AI-enabled, data-driven, and digitally integrated biomanufacturing systems. NMSC's analysis indicates that next-generation biomanufacturing is increasingly incorporating artificial intelligence, digital twins, and connected manufacturing data to improve process development, technology transfer, production efficiency, and regulatory readiness. The integration of these capabilities is expected to strengthen manufacturing scalability, process predictability, and operational flexibility across biologics production.

What Capital Inflows Are Targeting the Next-Generation Biomanufacturing Market?

Capital inflows into the next-generation biomanufacturing market are increasingly directed toward CDMO capacity expansion and connected digital platform development. We observed that investors favor companies demonstrating integrated equipment-software offerings and expanding CDMO capacity, viewing platform breadth as a proxy for long-term customer retention.

How Is Infrastructure Investment Supporting Next-Generation Biomanufacturing Market Delivery?

Infrastructure investment is expanding manufacturing capacity across Asia-Pacific, particularly in China and South Korea, to serve rising global biologics demand. Our findings suggest that suppliers are investing in continuous bioprocessing equipment manufacturing capacity to improve supply consistency across upstream and downstream product lines supporting growing biopharma and CDMO customer volumes.

What ESG Considerations Are Shaping Next-Generation Biomanufacturing Investment Decisions?

Environmental, social, and governance considerations increasingly factor into investment decisions, with single-use plastic waste reduction and energy efficiency of continuous manufacturing systems as key criteria. We found that investors increasingly favor companies with documented sustainable manufacturing roadmaps, treating single-use consumables recyclability as a governance indicator alongside energy consumption disclosure for large-scale biomanufacturing facilities.

How Does This Report Benefit Enterprise and Industry Leaders?

Enterprise and industry leaders gain access to validated segmentation, competitive benchmarking, and regional demand forecasts that support sourcing and technology-investment decisions across the next-generation biomanufacturing industry. Our analysis shows that detailed equipment, modality, and end-user breakdowns help procurement and manufacturing engineering teams align vendor selection with performance and integration requirements.

How Does This Report Benefit Investors and Financial Analysts?

Investors and financial analysts benefit from consistent, single-point market size and CAGR estimates that support valuation and capital-allocation decisions across the next-generation biomanufacturing supply chain. We observed that the report's regional and segment-level growth differentials help identify which equipment and services vendors are best positioned to capture above-market growth in automation and Asia-Pacific categories through 2035.

How Does This Report Benefit Technology Vendors and Product Teams?

Technology vendors and product teams gain insight into emerging requirements, including intensified downstream processing, real-time analytics, and specialized cell and gene therapy media, that are reshaping the industry. Our findings suggest that this analysis helps R&D teams prioritize development roadmaps around connected platform integration and modality-specific consumables increasingly required in CDMO and biopharma company procurement.

Key Market Segments Evaluated

By Equipment

Upstream systems
- Bioreactors and fermenters
- Perfusion and cell retention
- Media and buffer prep
- Other upstream equipment
Downstream systems
- Chromatography systems
- Filtration and TFF systems
- Clarification systems
- Other downstream equipment
Fill finish systems
- Aseptic filling
- Lyophilization
- Sterile transfer
- Other fill finish equipment
Automation and robotics
- Liquid handling robots
- Sampling and monitoring hardware
- Process control hardware
- Other automation hardware
Other equipment

By Consumables and raw materials

Single-use assemblies
- Bags and containers
- Tubing and manifolds
- Connectors and disconnectors
- Other single-use assemblies
Filtration and purification consumables
- Depth filters and capsules
- Membrane filters
- Prepacked columns and resins
- Other filtration consumables
Cell culture inputs
- Media
- Supplements and feeds
- Serum-free inputs
- Other cell culture inputs
Buffers and reagents
Sensors and probes
Other consumables

By Software and Digital Platforms

Data management
- Historian
- Batch records
- LIMS
Analytics and modelling
- PAT analytics
- Process simulation
- Digital twins
- Other analytics
Automation software
- SCADA
- DCS
- MES
- Other control software
Other software

By Technical services

Process development
Tech transfer and validation
CDMO and contract manufacturing
Engineering and integration
Quality control and testing
Training and support
Other services

By Workflow step

Upstream
Downstream
Fill-finish
Analytics and control
Cross-functional

By Technology architecture

Single-use
Stainless steel
Continuous
Modular
Hybrid

By Modality

Monoclonal antibodies
Vaccines
Cell therapy
Gene therapy
Recombinant proteins
MRNA
Plasmid DNA
Other biologics

By End Users

Biopharma Companies
CDMOs and CMOs
Academic and Research Institutions
Government and Public labs

By Sales channel

Direct key accounts
Distributor
System integrator
E-commerce and catalogue
Contract service

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Sweden
- Denmark
- Finland
- Netherlands
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- South Korea
- Taiwan
- Indonesia
- Vietnam
- Australia
- Philippines
- Malaysia
- Rest of APAC
Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Israel
- Turkey
- Nigeria
- South Africa
- Rest of MEA
Latin America
- Brazil
- Argentina
- Chile
- Colombia
- Rest of LATAM

Conclusion & Recommendations

The long-term outlook for the market remains highly positive, with global revenue projected to grow from USD 24.63 Billion in 2025 to USD 60.04 Billion by 2035 at a 9.32% CAGR. We observed that expanding CDMO capacity investment, rising cell and gene therapy manufacturing demand, and growing automation adoption will continue underpinning growth across biopharma, CDMO, and research institution customer segments through the forecast period.

What Strategic Positioning Should Next-Generation Biomanufacturing Vendors Pursue?

Vendors should prioritize connected, platform-level integration across equipment, software, and analytics while pursuing modality-specific consumables development to secure long-term customer contracts. Our assessment indicates that vendors investing early in real-time analytics and specialized cell and gene therapy inputs will be best positioned to capture premium pricing within the next-generation biomanufacturing market.

How Attractive Is the Next-Generation Biomanufacturing Market for New Investment?

The next-generation biomanufacturing industry presents a highly attractive investment case, supported by a USD 33.11 billion absolute dollar opportunity between 2026 and 2035 and above-average growth in Asia-Pacific and cell therapy categories. We found that investment attractiveness is highest for companies combining integrated equipment portfolios with digital platform capabilities, positioning them to serve both established biopharma and expanding CDMO customer segments simultaneously.

What Market Shifts and Key Risks Should Stakeholders Monitor?

Stakeholders should monitor the high capital cost of continuous manufacturing conversion, regulatory validation burden for novel technologies, and shortage of skilled bioprocess engineering talent as key risks to the next-generation biomanufacturing market. Our analysis shows that vendors unable to demonstrate validated, connected platform capabilities risk losing accounts to competitors with proven digital integration, particularly as CDMOs increasingly standardize procurement around platform-level vendor relationships.

What Are the Key Growth Pathways for the Next-Generation Biomanufacturing Market?

Key growth pathways include expanding integrated automation and analytics platforms, scaling specialized cell and gene therapy consumables, and deepening penetration into Asia-Pacific CDMO capacity expansion. NMSC's analysis indicates that vendors pursuing these pathways while maintaining interoperability across upstream and downstream equipment categories will be best positioned to capture the market's projected growth through 2035.

FAQs

About the Author

Mayurima Roy

Mayurima Roy is Research Analyst at Next Move Strategy Consulting, where she has spent 4 years working across the firm's full industry coverage rather than a single fixed vertical. Her work centers on structured research, ongoing trend tracking, competitive assessment, and insight-led content development, translating complex market data into clear, decision-ready narratives that support informed client decision-making across diverse global industries, market sectors, and world regions every day.

About the Reviewer

Supradip Baul

Supradip Baul is an accomplished business consultant and strategist with over a decade of rich experience in market intelligence, strategy, technology, and business transformation. His work has included rigorous qualitative and quantitative analysis across multiple industries, helping clients shape investment decisions and long-term roadmaps. Earlier in his career, he was associated with Gartner, where he contributed to industry-leading reports and market share analyses. He has worked with leading global companies and holds an MBA with a dual specialization in Marketing and Finance.

Download Free Sample

Full Name *

Business Email Id *

Country Code *

Phone Number *

Message

Yes, I have read the Privacy Policy

Testimonials

View All Testimonials

MOHIT AGARWAL

Chief Manager

Next Move Strategy Consulting is an amazing team of consultants. We required a market study report for our investors on top priority and the team went above and beyond our expectations to deliver the same with ample supporting data within a short time span enabling us to secure the investments and keep our project timeline maintained. Their professionalism, attention to detail, and timely delivery of actionable recommendations have left a lasting impression on our organization.

KISHU KANDA

Strategy Analyst

We purchased the AI Consumer Market Report from this company. Not only did they customize the report to meet our specific requirements, but they also showed great flexibility in accommodating our budget. The report we received fully met our expectations. Additionally, they provided prompt and thorough responses to both our pre-purchase and follow-up questions. We look forward to working with this company again in the future.

ROSS J MCKENZIE

Business Insight Manager

“Next MSC have been incredibly helpful in providing detailed & robust information on our market, alongside quantifying growth by different segments. The process to procure was simple and easy, with sample reports and regular contact to ensure we had what we needed. Succinct detail on their sources & methodologies is also greatly received, allowing transparency in this respect helps build trust in the detail you pay for. Joseph in particular was fantastic, and helped ensure efficient provision of the insight pack – thank you NMSC!”.

SEMIH KAVAKLIOGLU

Co-Founder & Sales Manager

I work a lot in the marketing industry and I know that research is an essential part of any campaign. I have used Market research reports for my own products and I found them to be very informative and well-researched. The team here produces insightful reports for a good price

ROBERT SEAN TREVINO

Sr. Director, Head of Strategic Insights & Analytics

I realized that it was a reliable source of information. These days, there are many people who are looking for authentic data, and this is one of the only sources that can offer them with what they need;

Next-Generation Biomanufacturing Market

Select License

Research Methodology

Qualitative Approach

Our Specialized Toolbox for Industry-Specific Market Research

Information Procurement

Market Research Approach

Porters Five Forces Analysis

SWOT Analysis

Forecasting

What Is the Next-Generation Biomanufacturing Market Size?

Next-Generation Biomanufacturing Market Revenue Forecast

Key Takeaways

Ecosystem Analysis of the Next-Generation Biomanufacturing Industry

What Does the Next-Generation Biomanufacturing Market Encompass?

Key Emerging Trends

How Is Intensified Downstream Processing Reshaping Purification Workflows?

Why Is Large-Scale Single-Use Capacity Expansion Accelerating Among CDMOs?

How Is At-Line Analytics Technology Compressing Bioprocess Decision Cycles?

What Role Does Specialized Cell and Gene Therapy Media Play in Manufacturing Scale-Up?

Market Drivers & Dynamics

Growth Drivers

What Is the Primary Growth Driver of the Next-Generation Biomanufacturing Market?

How Is Cell and Gene Therapy Demand Driving Market Growth?

Growth Inhibitors

What Is Restraining Next-Generation Biomanufacturing Market Expansion?

Segmentation Analysis

Which Equipment Segment Dominates the Next-Generation Biomanufacturing Market?

Which Modality Segment Leads Next-Generation Biomanufacturing Market Demand?

Which End User Segment Is Most Widely Served in the Market?

Growth Opportunities

How Can Integrated Automation Platforms Unlock Value for CDMOs?

Where Does Specialized Cell and Gene Therapy Media Create New Demand?

How Can Real-Time Analytics Benefit Continuous Manufacturing Adopters?

Regional Outlook

North America

Key National Markets

Europe

Key National Markets

Asia-Pacific

Key National Markets

Middle East & Africa

Key National Markets

Latin America

Key National Markets

Supply Chain Analysis of the Next-Generation Biomanufacturing Industry

Competitive Landscape

How Do Companies Compete in the Next-Generation Biomanufacturing Market?

Which Competitive Archetypes Dominate the Next-Generation Biomanufacturing Market?

How Are Companies Differentiating Through Innovation in the Market?

What M&A and Expansion Activity Is Shaping the Next-Generation Biomanufacturing Market?

Key Market Players

Latest Developments

Expert Insights

Justin Byers

Analyst Interpretation

What Capital Inflows Are Targeting the Next-Generation Biomanufacturing Market?

What Capital Inflows Are Targeting the Next-Generation Biomanufacturing Market?

How Is Infrastructure Investment Supporting Next-Generation Biomanufacturing Market Delivery?

What ESG Considerations Are Shaping Next-Generation Biomanufacturing Investment Decisions?

How Does This Report Benefit Enterprise and Industry Leaders?

How Does This Report Benefit Enterprise and Industry Leaders?

How Does This Report Benefit Investors and Financial Analysts?

How Does This Report Benefit Technology Vendors and Product Teams?

Key Market Segments Evaluated

By Equipment

By Consumables and raw materials

By Software and Digital Platforms

By Technical services

By Workflow step

By Technology architecture

By Modality

By End Users

By Sales channel

By Region

Conclusion & Recommendations

What Strategic Positioning Should Next-Generation Biomanufacturing Vendors Pursue?

How Attractive Is the Next-Generation Biomanufacturing Market for New Investment?

What Market Shifts and Key Risks Should Stakeholders Monitor?

What Are the Key Growth Pathways for the Next-Generation Biomanufacturing Market?